A Phase 1b, Open-label, Randomized, Multicenter, Active Comparator Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Combination of APG777 + APG990 in Adults With Moderate-to-Severe Atopic Dermatitis

The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).

Start Date04 Jun 2025

Sponsor / Collaborator

Apogee Therapeutics, Inc.

NCT07003425

/ RecruitingPhase 2

A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).
The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.
This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.

Start Date14 May 2025

Sponsor / Collaborator

Apogee Therapeutics, Inc.

NCT06920901

/ Active, not recruitingPhase 1

A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of APG777 in Adults With Mild-to-Moderate Asthma

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma.
The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.

Start Date27 Mar 2025

Sponsor / Collaborator

Apogee Therapeutics, Inc.

100 Clinical Results associated with Zumilokibart

100 Translational Medicine associated with Zumilokibart

100 Patents (Medical) associated with Zumilokibart

Literatures (Medical) associated with Zumilokibart

23 Mar 2026·Cureus Journal of Medical Science

Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents

Review

Author: Soliman, Yssra ; Babul, Najib ; Babul, Arya ; Mehta, Devina ; Hussain, Momina

Biologic therapies targeting maladaptive type 2 inflammation have transformed the management of moderate‑to‑severe atopic dermatitis (AD); however, comparative evidence integrating both approved and next‑generation investigational agents remains limited. This Bayesian network meta‑analysis (BNMA) provides the first unified evaluation of all biologic monoclonal antibodies approved as monotherapy for AD (dupilumab, lebrikizumab, tralokinumab) together with emerging immunotherapies, including amlitelimab, rademikibart, rezpegaldesleukin, rocatinlimab, telazorlimab, temtokibart, and zumilokibart, across key efficacy measures. A PRISMA‑2020-compliant systematic review and PROSPERO‑registered protocol (CRD420251162704) identified phase 2-3 randomized, double‑blind, placebo‑controlled trials reporting week‑16 outcomes (week‑24 for rocatinlimab). A Bayesian random‑effects NMA estimated relative risks (RRs) for EASI‑75, EASI‑90, IGA‑AD 0/1, and ≥4‑point improvement in itch Numeric Rating Scale (NRS). Treatment hierarchy was evaluated using both Bayesian (SUCRA) and frequentist (P‑score) approaches. Seventeen randomized controlled trials (RCTs) involving more than 6,000 patients were included in the analysis. Dupilumab demonstrated the most consistent and reliable efficacy across all evaluated endpoints, including improvements in EASI-75, EASI-90, IGA-AD 0/1, and itch NRS. Among investigational therapies, rocatinlimab showed a notable signal for deep clinical responses, although the available evidence remains limited and less precise. Other emerging agents, including rademikibart, temtokibart, and zumilokibart, demonstrated encouraging efficacy profiles, whereas telazorlimab showed comparatively modest clinical benefit. Ranking analyses consistently positioned dupilumab as the most reliable and highest-performing therapy overall, followed by rocatinlimab. Overall, biologic therapies were generally well tolerated in the short term; however, dupilumab remains the only agent supported by extensive long-term safety data extending up to a decade. This analysis relied on indirect comparisons anchored to short‑term placebo‑controlled induction periods, limiting assessment of long‑term safety and durability, particularly for mechanistically distinct agents such as rezpegaldesleukin, a regulatory T cell (Treg) pathway agonist, and rocatinlimab, an OXO pathway inhibitor. Evidence for several emerging therapies was restricted to small phase 2 trials, resulting in wide credible intervals (Crls) and lower certainty in comparative rankings. Trial heterogeneity in baseline severity, ethnic composition, and geographic setting may have introduced residual confounding despite sensitivity and meta‑regression analyses. These factors should be considered when interpreting relative efficacy estimates This NMA demonstrates that dupilumab remains the most reliable and effective biologic monotherapy for moderate‑to‑severe AD, supported by the greatest precision, reproducibility, and long‑term safety. Rocatinlimab shows promising investigational efficacy but requires efficacy and long-term safety validation. Zumilokibart, rademikibart, and temtokibart emerge as additional candidates with encouraging activity, whereas telazorlimab showed limited clinical benefit. Collectively, these findings provide a comprehensive comparative framework to inform biologic selection and therapeutic sequencing.

01 Dec 2025·CTS-Clinical and Translational Science

A First‐in‐Human, Single‐ and Multiple‐Dose Study of APG777 , a Half‐Life‐Extended Anti‐ IL ‐13 Monoclonal Antibody, in Healthy Volunteers

Article

Author: Thankamony, Sai ; Winter, Erica ; Nograles, Kristine ; Zhang, Zhi‐Qiang ; Dambkowski, Carl L. ; Dillinger, Lukas ; Lim, Xiu Qin ; Xu, Jiahong

ABSTRACT:

Interleukin (IL)‐13 plays a central role in Type 2 inflammation, contributing to the pathogenesis of atopic dermatitis, asthma, and related inflammatory diseases. APG777 is a novel anti‐IL‐13 monoclonal antibody engineered for improved pharmacokinetics and reduced dosing frequency. This first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple subcutaneous doses of APG777 in healthy adults. Forty participants were enrolled in single ascending dose (300–1200 mg) and multiple dose (300 mg × 2) cohorts. APG777 was well tolerated, with only mild‐to‐moderate treatment‐emergent adverse events, predominantly unrelated to the study drug. No serious or severe drug‐related treatment‐emergent adverse events occurred. Following single doses, APG777 exhibited dose‐proportional increases in Cmax and area under the curve, with a terminal half‐life ranging from 75.3 to 77.5 days across the dose range tested. Immunogenicity was low, with anti‐drug antibodies detected in 23.3% of treated participants, generally without impact on pharmacokinetics or safety. APG777 led to rapid and durable inhibition of the IL‐13‐driven biomarkers phosphorylated signal transducer and activator of transcription 6 (pSTAT6), thymus and activation‐regulated chemokine (TARC), and immunoglobulin E (IgE), with near‐complete suppression of pSTAT6 observed for up to 12 months post‐dose. The safety and optimized pharmacokinetic profile of APG777 supports evaluation of extended dosing intervals (every 3–6 months) and higher exposures, which could improve outcomes and reduce injection burden in patients with Type 2 inflammatory diseases including atopic dermatitis and asthma.

01 Dec 2025·INTERNATIONAL JOURNAL OF TOXICOLOGY

Preclinical Safety of APG777, A Novel Extended Half-Life Anti-Interleukin-13 Monoclonal Antibody, in Cynomolgus Monkeys

Article

Author: Rubio, Daniel ; Badger, Drew ; Zhu, Eric ; Funk, Kathleen A. ; Thurston, Archie ; York, Kristina A. ; Dambkowski, Carl L.

Interleukin-13 (IL-13) is a cytokine implicated in the pathophysiology of type 2 inflammatory diseases and is a clinically validated target in atopic dermatitis. APG777 is a humanized IgG1 monoclonal antibody with an optimized pharmacokinetic profile. APG777 has high affinity to IL-13 and includes a triple amino acid modification (the “YTE” modification) in its Fc region that is designed to extend its half-life. The current study examined the safety and potential toxicity of APG777 when given by once-weekly subcutaneous injection for 27 weeks to cynomolgus monkeys, and the potential reversibility of any findings following a 2-month recovery period. Toxicokinetic characteristics of APG777 were also determined. APG777 exhibited dose-proportional systemic exposure, with a half-life of approximately 28 days. No APG777-related adverse effects were noted in clinical observations, body weight, ophthalmology, electrocardiogram readings, neurologic parameters, hematology, coagulation, clinical chemistry, urinalysis, organ weights, or histopathology. Anti-drug antibodies were not detected in any APG777-exposed animals. Drug accumulation was evident over the study duration; however, there were no APG777-related adverse findings in any of the parameters analyzed. The no-observed-adverse-effect level (NOAEL) was 150 mg/kg/week. These findings provide preclinical evidence supporting continued clinical development of APG777 for IL-13-mediated diseases. The extended half-life of APG777 suggests potential benefits in reducing dosing frequency compared with existing IL-13-targeting therapies, which could improve treatment adherence and patient outcomes. The safety and efficacy of APG777 are currently being investigated in a Phase 2 clinical trial (NCT06395948) in patients with moderate-to-severe atopic dermatitis.

News (Medical) associated with Zumilokibart

25 Jun 2026

·www.biopharmadive.com

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie is making its biggest acquisition in years in a bid to expand its portfolio of autoimmune disease drugs, announcing on Monday plans to buy Apogee Therapeutics for nearly $11 billion. The pharmaceutical giant will pay $135.11 per share for Apogee, a roughly 49% premium to the biotechnology company’s closing price on Friday. The acquisition should close in the third quarter of 2026, pending approvals from shareholders and regulatory agencies. The Financial Times first reported news of a pending deal on Friday. The purchase is AbbVie’s largest since taking over Botox maker Allergan in a $63 billion deal in 2019. It also surpasses the company’s big-ticket buyouts of ImmunoGen and Cerevel Therapeutics in 2023, two deals AbbVie used to add medicines for cancer and neurological diseases. For the biotechnology sector, the buyout adds to a particularly active year for company purchases. So far, 32 deals have been struck with at least $50 million in guaranteed upfront payments. Around two thirds of those deals have been worth at least $1 billion and six have eclipsed $5 billion. Both totals are on pace to surpass what’s been seen in every year since at least 2020, according to BioPharma Dive data. In acquiring Apogee, AbbVie is adding to an armamentarium of inflammatory disease medicines that has long been its core focus. That portfolio was long led by Humira, which made more than $200 billion for AbbVie before going off-patent, and now includes newer drugs like Skyrizi and Rinvoq that are used to treat conditions such as psoriasis, Crohn’s disease and eczema. Apogee’s top drug, zumilokibart, is being positioned as a competitor to widely used antibody-based drugs for eczema and asthma, such as Sanofi and Regeneron Pharmaceuticals’ Dupixent. Whereas Dupixent is injected every two weeks, zumilokibart offers the potential for anywhere from two to four injections per year. It also works slightly differently than Dupixent, precisely binding to the inflammatory cytokine IL-13 rather than a receptor shared by IL-13 and a different signaling protein. The result is a drug that might be more potent and convenient than other injections. In its statement, AbbVie noted how a large majority of people with atopic dermatitis still don’t see both relief from itching, as well as improvements in skin clearance. Phase 2 testing showed that about two-thirds of treatment recipients had “significant” skin clearance after 16 weeks, along with “notable improvements” in itching. Those findings, along with a safety profile that’s consistent with other, similar medications, support zumilokibart’s “best-in-class” profile, AbbVie said. Phase 3 testing had been expected to start later this year. Apogee has a pipeline of other longer-lasting immune drugs in earlier testing as well. One, APG273, combines zumilokibart with another antibody that blocks a signaling protein, TSLP, implicated in lung inflammation. Early data suggest that it could be useful in treating asthma and injected either quarterly or twice per year. “Apogee's pipeline adds highly differentiated clinical-stage assets, further expanding our robust immunology portfolio in areas of significant patient need, including atopic dermatitis and asthma,” said AbbVie CEO Robert Michael, in a statement. For Apogee, the buyout is an “ideal and sensible outcome,” but comes “earlier than we would have expected,” wrote RBC Capital Markets analyst Brian Abrahams. To Abrahams, it “remains possible” that other suitors could come forward, as zumilokibart might be a fit for “many other large pharma players,” such as Sanofi or Johnson & Johnson. AbbVie, though, could maximize the drug’s potential to achieve “mega-blockbuster status,” Stifel analyst Alex Thompson added in a separate note. AbbVie is a “natural acquirer” for Apogee and buying the company now could minimize the royalty payments owed by Apogee to Blackstone Life Sciences under a recent financing deal, he wrote. Apogee is one of several immune disease-focused spinouts of antibody drug specialist Paragon Therapeutics. A few others, among them Spyre Therapeutics and Oruka Therapeutics, are now publicly traded and worth billions of dollars. The content above comes from the network. if any infringement, please contact us to modify.

AcquisitionImmunotherapyClinical Result

23 Jun 2026

·www.prnewswire.com

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthma Apogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billion June 22, 2026 -- AbbVie (NYSE: ABBV) and Apogee Therapeutics (NASDAQ: APGE) ("Apogee") today announced they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma. The acquisition complements AbbVie's existing immunology portfolio and accelerates AbbVie's clinical presence in the respiratory space. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. The transaction values Apogee at a total equity value of approximately $10.9 billion. The boards of directors of both companies have unanimously approved the transaction. This transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals. "For more than two decades, AbbVie has led and shaped the field of immunology bringing the science, scale and expertise needed to address some of the most complex diseases," said Robert A. Michael, chairman and chief executive officer, AbbVie. "The acquisition of Apogee further builds on our existing leadership, strengthening our ability to deliver innovative medicines to patients who need better options while also creating significant long-term value for shareholders. Apogee's pipeline adds highly differentiated clinical-stage assets, further expanding our robust immunology portfolio in areas of significant patient need, including atopic dermatitis and asthma. With our deep scientific expertise and proven capabilities, we are uniquely positioned to rapidly advance these programs and continue to transform the standard of care in inflammatory diseases." This acquisition holds potential for substantial shareholder value creation with mega-blockbuster peak sales potential across Apogee's pipeline of assets, including its lead asset, zumilokibart (APG777), a subcutaneous half-life extended monoclonal antibody targeting IL-13, being developed in AD and APG273, a combination of zumilokibart and APG333, an anti-TSLP half-life extended monoclonal antibody, being developed in asthma."This transaction reflects the strength of Apogee's vision, our team's dedication and the significant progress we've made advancing zumilokibart and our differentiated pipeline," said Michael Henderson, M.D., chief executive officer, Apogee. "Since our founding, we've focused on developing transformative therapies for patients with inflammatory diseases while creating value for shareholders. This transaction delivers substantial shareholder value and positions our programs to reach their full potential. We are deeply grateful to the patients, physicians and investigators who helped make this milestone possible. We believe AbbVie can advance zumilokibart and our portfolio while expanding their impact for patients worldwide." Zumilokibart targets IL-13, a critical cytokine in type 2 inflammation, and a central driver of inflammatory diseases like AD and asthma. Specifically in AD, a large majority of patients do not achieve simultaneous itch and skin improvement which represents an opportunity for the development of novel treatments that not only provide better skin clearance and itch resolution but also improve convenience with less frequent dosing. In its Phase 2 clinical trial, zumilokibart attained clinically significant results, with approximately two-thirds of patients on treatment achieving significant skin clearance at 16 weeks, along with notable improvements in itch reduction and overall disease control. These findings support its potential best-in-category profile, including strong efficacy and significantly improved dosing, in patients with AD. Longer-term data from the same trial also supports highly convenient maintenance regimens of either quarterly or twice a year dosing. The safety profile of zumilokibart is favorable and consistent with other medicines in its class, and the molecule has the potential to be evaluated in several additional inflammatory indications. Beyond zumilokibart, Apogee has built a broader pipeline of novel antibodies targeting multiple validated inflammatory pathways. APG273 combines zumilokibart with APG333, an antibody that blocks TSLP, a signaling protein that acts as an early trigger of inflammation in the lungs. Phase 1 data showed that APG333 has a long half-life and was able to suppress relevant type 2 inflammatory markers for up to six months after dosing. The Phase 1 data with APG333 and positive interim results from a phase 1b study of zumilokibart in asthma, supports the potential of the APG273 combination with quarterly or twice-yearly injections in asthma. Under the terms of the definitive agreement, AbbVie will acquire all outstanding Apogee common stock for $135.11 per share in cash. The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by Apogee shareholders. Fairmount Funds Management LLC and Venrock Associates have entered into voting agreements in support of the transaction. The proposed transaction is expected to be accretive to AbbVie's adjusted diluted earnings per share (EPS) beginning in 2032. AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of actions and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease. Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultImmunotherapyAcquisition

23 Jun 2026

·pmlive.com

AbbVie to acquire Apogee Therapeutics in $10.9bn deal

AbbVie has announced it will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma. The acquisition complements AbbVie’s existing immunology portfolio and accelerates AbbVie’s clinical presence in the respiratory space. Robert Michael, chairman and CEO at AbbVie, said: “The acquisition of Apogee further builds on our existing leadership, strengthening our ability to deliver innovative medicines to patients who need better options while also creating significant long-term value for shareholders. Apogee’s pipeline adds highly differentiated clinical-stage assets, further expanding our robust immunology portfolio in areas of significant patient need, including atopic dermatitis and asthma.” Apogee’s lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis (AD). Zumilokibart targets IL-13, a critical cytokine in type 2 inflammation and a central driver of inflammatory diseases like AD and asthma. Specifically in AD, a large majority of patients do not achieve simultaneous itch and skin improvement, which represents an opportunity for the development of novel treatments that not only provide better skin clearance and itch resolution but also improve convenience with less frequent dosing. Apogee’s pipeline also includes combinations of its novel antibodies: APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthma. Michael Henderson, CEO at Apogee, commented: “Since our founding, we’ve focused on developing transformative therapies for patients with inflammatory diseases. We believe AbbVie can advance zumilokibart and our portfolio while expanding their impact for patients worldwide.” The transaction is expected to close in the third quarter of 2026.

ImmunotherapyAcquisition

100 Deals associated with Zumilokibart

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Moderate Atopic Dermatitis	Phase 2	United States	Apogee Therapeutics, Inc.	29 Apr 2024
Moderate Atopic Dermatitis	Phase 2	Canada	Apogee Therapeutics, Inc.	29 Apr 2024
Moderate Atopic Dermatitis	Phase 2	Czechia	Apogee Therapeutics, Inc.	29 Apr 2024
Moderate Atopic Dermatitis	Phase 2	France	Apogee Therapeutics, Inc.	29 Apr 2024
Moderate Atopic Dermatitis	Phase 2	Germany	Apogee Therapeutics, Inc.	29 Apr 2024
Moderate Atopic Dermatitis	Phase 2	Hungary	Apogee Therapeutics, Inc.	29 Apr 2024
Moderate Atopic Dermatitis	Phase 2	Poland	Apogee Therapeutics, Inc.	29 Apr 2024
Moderate Atopic Dermatitis	Phase 2	Spain	Apogee Therapeutics, Inc.	29 Apr 2024
Moderate Atopic Dermatitis	Phase 2	United Kingdom	Apogee Therapeutics, Inc.	29 Apr 2024
Severe Atopic Dermatitis	Phase 2	United States	Apogee Therapeutics, Inc.	29 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06395948 (APXZP002, AAD2026)	Phase 2	Dermatitis, Atopic	123	APG777 (moderate AD (16≤EASI≤21 or vIGA-AD=3))	rmxbpudoht(dtrukdudty) = occurring in ≥5% of APG777-treated participants included noninfective conjunctivitis and upper respiratory tract infection xuajymqrro (uzgjxdipwh )	Positive	27 Mar 2026
				APG777 (severe AD (EASI>21 or vIGA-AD=4))
NCT06395948 (APEX, AAD2026)	Phase 2	Dermatitis, Atopic	123	APG777	ytjkarimnq(gwmmphxcdn) = occurring in 6 5% of APG777-treated participants included noninfective conjunctivitis and upper respiratory tract infection. ghnpazugkt (frbtlkrujw ) View more	Positive	27 Mar 2026
				Placebo
NCT06395948 (APEX, Company_Website) Manual	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	-	Zumilokibart (APG777) 3-month dosing	aimxyigmae(xqpsiybryl) = jzdjrwkhdz qmpsubvezz (umxrdljfmx ) View more	Positive	23 Mar 2026
				Zumilokibart (APG777) 6-month dosing	aimxyigmae(xqpsiybryl) = ruhodmscqx qmpsubvezz (umxrdljfmx ) View more
NCT06395948 (APEX Part A, AAAAI2026)	Phase 2	Dermatitis, Atopic	123	APG777	imarmxfexj(ixxbapsopm): P-Value = <0.001 View more	Positive	27 Feb 2026
				Placebo
NCT06395948 (APEX Part A, AAAAI2026)	Phase 2	Dermatitis, Atopic	123	APG777 (with evidence of type 2 comorbidities)	ublvtjfalo(hogjeabixb) = sradyokims ktfhpitvrz (ttsldstchc )	Positive	27 Feb 2026
				Placebo (with evidence of type 2 comorbidities)	ublvtjfalo(hogjeabixb) = rcyvraenoh ktfhpitvrz (ttsldstchc )
NCT06395948 (APEX, GlobeNewswire) Manual	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis \| Dermatitis	123	APG777	psqdjgprsq(uznvmbrxqn) = ixvfwpvcqo mxxhryyguq (evsclldrzb ) Met View more	Positive	07 Jul 2025
				placebo	psqdjgprsq(uznvmbrxqn) = esjxscxiuv mxxhryyguq (evsclldrzb ) Met View more
ACTRN12623000786695 (GlobeNewswire) Manual	Phase 1	-	40	APG777	uwpoacflno(biemxzpydk) = axkjwwrqxo xxsubvbhcy (xtorbxlhff ) View more	Positive	05 Mar 2024
				placebo	-
NCT06395948 (APG777, EADV2023)	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis IL-13	-	APG777	wplfhbulkd(wyjdxhfrxb) = ssyfnckicu gzjbfbyuhz (bldylhapsy )	Positive	11 Oct 2023
				Lebrikizumab	wplfhbulkd(wyjdxhfrxb) = tffzxphror gzjbfbyuhz (bldylhapsy )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis